Pillar Biosciences Receives China National Medical Products Administration (NMPA) Approval for oncoRevealTM Dx Colon Cancer Assay
Pillar Biosciences , the leader in Decision Medicine, developers and distributors of next-generation sequencing (NGS) tests which localize testing and reduce time to treatment initiation and overall testing costs, today announced that its oncoRevealTM Dx Colon Cancer Assay has received approval from the China National Medical Products Administration (NMPA).